SUSVIMO® is clinically proven to deliver vision results equal to monthly injections with just 2 treatments per year.†‡
SUSVIMO® is clinically proven to deliver vision results equal to monthly injections with just 2 treatments per year.†‡
For patients with wet AMD previously treated with at least 2 intravitreal injections of a VEGF inhibitor medication.
†In a clinical trial, SUSVIMO patients maintained vision as well as patients on monthly ranibizumab injections at weeks 36 and 40, as measured by the best corrected visual acuity score. There was a temporary decrease in vision after the SUSVIMO procedure.
‡In certain cases, you may be given an additional treatment in the SUSVIMO-treated eye if your Retina Specialist decides it is necessary.
The first and only device for people with wet AMD that continuously delivers treatment over 6 months.
Listen to real patients talk about their experience with SUSVIMO, how their lives have changed since the implant.
Access downloadable brochures and guides to help you or your loved one.
AMD=age-related macular degeneration; VEGF=vascular endothelial growth factor.
For patients with wet AMD previously treated with at least 2 intravitreal injections of a VEGF inhibitor medication.
†In a clinical trial, SUSVIMO patients maintained vision as well as patients on monthly ranibizumab injections at weeks 36 and 40, as measured by the best corrected visual acuity score. There was a temporary decrease in vision after the SUSVIMO procedure.
‡In certain cases, you may be given an additional treatment in the SUSVIMO-treated eye if your Retina Specialist decides it is necessary.
The first and only device for people with wet AMD that continuously delivers treatment over 6 months.
Listen to real patients talk about their experience with SUSVIMO, how their lives have changed since the implant.
Access downloadable brochures and guides to help you or your loved one.
AMD=age-related macular degeneration; VEGF=vascular endothelial growth factor.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech, Inc. does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.